Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C22orf46P (chromosome 22 open reading frame 46, pseudogene) is annotated as a pseudogene in the human genome and therefore does *not* encode a functional protein product under standard genomic annotation conventions[1][4][7]. However, there is some ambiguity and potential confusion in the literature. The parent gene name "C22orf46" (sometimes also referred to as FLJ23584 or CTA-216E10.6) has been suggested by recent studies to actually encode a nuclear/nucleolar protein, called Tumor Apoptosis Associated Protein 1 (TAAP1), with roles in anti-apoptotic signaling in some cancer models[2]. This newly suggested function is for C22orf46/FLJ23584, not explicitly the pseudogene C22orf46P, which is officially annotated as a non-functional genomic element. For C22orf46P (the pseudogene, with 'P'), there is **no evidence of a therapeutic target role or interaction with drugs, nor any validated biological or disease function**[1][4][7]. There are no reported biomarkers, mechanisms of action, or safety concerns. The use of this symbol as a target is incorrect—C22orf46P itself is not considered a protein-coding target in drug discovery or therapeutics. The confusion stems from closely related names in the literature: **C22orf46** (without 'P'), whose product (FLJ23584/TAAP1) may have actual biological relevance in cancer and apoptosis[2]. Therefore, if your intent is a therapeutic target, be aware: - **C22orf46P** is a pseudogene and not a target. - **C22orf46 (TAAP1/FLJ23584)**, not the pseudogene, may encode a functional anti-apoptotic protein, but this is an emerging area and not yet standard nomenclature. If you require structured information for a therapeutic or biomarker role, you should refer to “C22orf46” (without 'P') or “Tumor Apoptosis Associated Protein 1” (TAAP1) instead[2]. **Summary:** C22orf46P is a pseudogene, not a therapeutic target; using it as a drug target is incorrect. If you are seeking biologically meaningful target information, reference C22orf46 (TAAP1) instead[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 22 open reading frame 46, pseudogene (C22orf46P).